BIOSIM Act
The source supplies the latest action, but no lifecycle stage.
Latest action (23 Apr 2021): Referred to the Subcommittee on Health.
What this bill does
The BIOSIM Act, introduced in the House of Representatives, would temporarily increase Medicare Part B payments for certain biosimilar drugs. For a period of five years, the payment rate for qualifying biosimilars would be increased by 8 percent, instead of the current 6 percent. This increase would apply to biosimilars whose average sales price or wholesale acquisition cost is less than that of the reference biological product.
This legislation affects Medicare beneficiaries who use these specific biosimilar drugs and the healthcare providers who administer them. The bill aims to encourage the development and use of biosimilars by making them more financially attractive under Medicare's payment system.
The bill was introduced on April 22, 2021, and referred to the House Committees on Energy and Commerce, and Ways and Means. As of its introduction, it has not advanced further in the legislative process. If passed by both houses of Congress and signed by the President, it would amend the Social Security Act.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act
This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.
Timeline
23 Apr 2021
Referred to the Subcommittee on Health.
Common questions
- What does H.R. 2815 do?
- The BIOSIM Act, introduced in the House of Representatives, would temporarily increase Medicare Part B payments for certain biosimilar drugs. For a period of five years, the payment rate for qualifying biosimilars would be increased by 8 percent, instead of the current 6 percent. This increase would apply to biosimilars whose average sales price or wholesale acquisition cost is less than that of the reference biological product. This legislation affects Medicare beneficiaries who use these specific biosimilar drugs and the healthcare providers who administer them. The bill aims to encourage the development and use of biosimilars by making them more financially attractive under Medicare's payment system. The bill was introduced on April 22, 2021, and referred to the House Committees on Energy and Commerce, and Ways and Means. As of its introduction, it has not advanced further in the legislative process. If passed by both houses of Congress and signed by the President, it would amend the Social Security Act.
- Has H.R. 2815 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 2815. Check the latest action and official source below.
- Who sponsored H.R. 2815?
- H.R. 2815 was sponsored by Rep. Schrader, Kurt [D-OR-5] (D-OR), with 4 cosponsors.
- What's the latest action on H.R. 2815?
- Referred to the Subcommittee on Health. (23 Apr 2021).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Silicosis Prevention and Treatment Act
340B Rebate Model Delay Act
More bills from Rep. Schrader, Kurt [D-OR-5]
BIOSIM Act
Encouraging the Secretaries of the military departments to maximize opportunities for space-available travel for members of the Armed Forces in a leave or pass status who are traveling between December 18, 2009, and January 3, 2010.
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.